VX-147
VX22-147-010
Phase 1 small_molecule completed
Quick answer
VX-147 for Focal Segmental Glomerulosclerosis (FSGS) is a Phase 1 program (small_molecule) at Vertex Pharmaceuticals (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Vertex Pharmaceuticals (Ireland) Limited
- Indication
- Focal Segmental Glomerulosclerosis (FSGS)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed